Logo image of ADOC.PA

ADOCIA SAS (ADOC.PA) Stock Fundamental Analysis

EPA:ADOC - Euronext Paris - Matif - FR0011184241 - Common Stock - Currency: EUR

3.82  +0.06 (+1.73%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADOC. ADOC was compared to 73 industry peers in the Biotechnology industry. Both the profitability and financial health of ADOC have multiple concerns. ADOC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADOC has reported negative net income.
ADOC had a negative operating cash flow in the past year.
ADOC had negative earnings in each of the past 5 years.
In the past 5 years ADOC always reported negative operating cash flow.
ADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFADOC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

The Return On Assets of ADOC (-34.50%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROIC N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADOC.PA Yearly ROA, ROE, ROICADOC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

With an excellent Gross Margin value of 87.98%, ADOC belongs to the best of the industry, outperforming 84.93% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for ADOC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADOC.PA Yearly Profit, Operating, Gross MarginsADOC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

2

2. Health

2.1 Basic Checks

ADOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADOC has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADOC has been increased compared to 5 years ago.
ADOC has a better debt/assets ratio than last year.
ADOC.PA Yearly Shares OutstandingADOC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
ADOC.PA Yearly Total Debt VS Total AssetsADOC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ADOC has an Altman-Z score of -0.93. This is a bad value and indicates that ADOC is not financially healthy and even has some risk of bankruptcy.
ADOC has a Altman-Z score (-0.93) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.93
ROIC/WACCN/A
WACC7.39%
ADOC.PA Yearly LT Debt VS Equity VS FCFADOC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.08 indicates that ADOC should not have too much problems paying its short term obligations.
The Current ratio of ADOC (1.08) is worse than 69.86% of its industry peers.
ADOC has a Quick Ratio of 1.07. This is a normal value and indicates that ADOC is financially healthy and should not expect problems in meeting its short term obligations.
ADOC has a worse Quick ratio (1.07) than 65.75% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.07
ADOC.PA Yearly Current Assets VS Current LiabilitesADOC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.43% over the past year.
Looking at the last year, ADOC shows a very strong growth in Revenue. The Revenue has grown by 333.49%.
The Revenue has been growing by 34.18% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%

3.2 Future

Based on estimates for the next years, ADOC will show a small growth in Earnings Per Share. The EPS will grow by 2.80% on average per year.
The Revenue is expected to grow by 17.84% on average over the next years. This is quite good.
EPS Next Y-26.35%
EPS Next 2Y-22.56%
EPS Next 3Y-55.87%
EPS Next 5Y2.8%
Revenue Next Year-18.75%
Revenue Next 2Y-15.59%
Revenue Next 3Y-6.44%
Revenue Next 5Y17.84%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ADOC.PA Yearly Revenue VS EstimatesADOC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
ADOC.PA Yearly EPS VS EstimatesADOC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADOC. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 0.86 indicates a rather cheap valuation of ADOC.
100.00% of the companies in the same industry are more expensive than ADOC, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.19, ADOC is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 0.86
ADOC.PA Price Earnings VS Forward Price EarningsADOC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADOC.PA Per share dataADOC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

ADOC's earnings are expected to decrease with -55.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.56%
EPS Next 3Y-55.87%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADOC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADOCIA SAS

EPA:ADOC (6/20/2025, 2:07:30 PM)

3.82

+0.06 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14
Earnings (Next)07-23 2025-07-23
Inst Owners14.87%
Inst Owner ChangeN/A
Ins Owners9.82%
Ins Owner ChangeN/A
Market Cap69.10M
Analysts85.71
Price Target9.33 (144.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.86
P/S 7.41
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.65
EYN/A
EPS(NY)4.45
Fwd EY116.42%
FCF(TTM)-0.88
FCFYN/A
OCF(TTM)-0.86
OCFYN/A
SpS0.52
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.98%
FCFM N/A
ROA(3y)-47.28%
ROA(5y)-53.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.02%
Cap/Sales 2.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.07
Altman-Z -0.93
F-Score5
WACC7.39%
ROIC/WACCN/A
Cap/Depr(3y)32.19%
Cap/Depr(5y)28.97%
Cap/Sales(3y)3.68%
Cap/Sales(5y)12.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.28%
EPS Next Y-26.35%
EPS Next 2Y-22.56%
EPS Next 3Y-55.87%
EPS Next 5Y2.8%
Revenue 1Y (TTM)333.49%
Revenue growth 3Y86.19%
Revenue growth 5Y34.18%
Sales Q2Q%1682.03%
Revenue Next Year-18.75%
Revenue Next 2Y-15.59%
Revenue Next 3Y-6.44%
Revenue Next 5Y17.84%
EBIT growth 1Y48.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.86%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-210.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-215.33%
OCF growth 3YN/A
OCF growth 5YN/A